Eli Lilly的Q2收入比预期高,而糖尿病和肥胖症药品销售强劲,导致2025年利润预测增加。 Eli Lilly's Q2 earnings beat expectations, fueled by strong sales of diabetes and obesity drugs, leading to a raised 2025 profit forecast.

Eli Lilly和公司报告说,第二季度收入强劲,调整后的EPS收入为6.31美元,超过估计的7.72美元和15.56亿美元收入,年年增长37.6%,其驱动因素是对糖尿病和肥胖症治疗的需求,如Mounjaro和Zepbound。 Eli Lilly and Company reported strong second-quarter earnings, with $6.31 in adjusted EPS, surpassing estimates by $0.72, and $15.56 billion in revenue, a 37.6% year-over-year increase, driven by demand for diabetes and obesity treatments like Mounjaro and Zepbound. 该公司将其2025年全年EPS指导提高到21.75至23.00美元,分析师预测为23.48美元。 The company raised its 2025 full-year EPS guidance to $21.75–$23.00, with analysts forecasting $23.48. 股票交易额为724.73美元,市场上限为6 855.93亿美元,P/E比率为47.37,协商一致的“机动购买”评级为939.61美元,目标价格为939.61美元。 Trading at $724.73, the stock has a market cap of $685.93 billion, a P/E ratio of 47.37, and a consensus "Moderate Buy" rating with a target price of $939.61. 本季度,内部人士集体购买了4 514股股票,价值近290万美元,而一些机构投资者调整了他们的股份。 Insiders collectively purchased 4,514 shares worth nearly $2.9 million in the quarter, while several institutional investors adjusted their stakes. 该公司保持强劲的金融业务,包括92.72%的股本回报率和25.91%的净差值。 The company maintains strong financials, including a 92.72% return on equity and 25.91% net margin.